Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02532998
Other study ID # D6400C00004
Secondary ID 2015-002224-11
Status Completed
Phase Phase 1
First received August 24, 2015
Last updated December 22, 2015
Start date September 2015
Est. completion date December 2015

Study information

Verified date December 2015
Source AstraZeneca
Contact n/a
Is FDA regulated No
Health authority United Kingdom: Medicines and Healthcare Products Regulatory Agency
Study type Interventional

Clinical Trial Summary

This is a Phase I, Randomized, Single-Blind, Crossover Study to Assess the Pharmacodynamics of AZD9977 following Single-Dose administration to healthy male subjects


Description:

This study will be a phase I study to assess the pharmacodynamics of AZD9977 following single-dose administration to healthy male subjects. It is a single-blind (with regards to AZD9977 and AZD9977 Placebo), randomized, four-treatment, four-period crossover design, with a potential 5th and 6th randomized cross-over treatment period. In this study eplerenone is used as a positive control and fludrocortisone will be used as a challenge agent. In addition the safety, tolerability and pharmacokinetics will be assessed.


Recruitment information / eligibility

Status Completed
Enrollment 24
Est. completion date December 2015
Est. primary completion date December 2015
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 50 Years
Eligibility Inclusion criteria

1. Provision of signed and dated written informed consent prior to any study specific procedures.

2. Healthy male subjects aged 18 to 50 years with suitable veins for cannulation or repeated venipuncture.

3. Male subjects must accept to comply with the restrictions for sexual activity provided to them.

4. Have a body mass index (BMI) between 18 and 30 kg/m2 inclusive and weigh at least 50 kg and no more than 100 kg inclusive.

5. Optional: Provision of signed and dated written informed consent for genetic research.

Note: Participation in exploratory biomarker research is mandatory. If a subject declines to participate in the genetic component of the study, there will be no penalty or loss of benefit to the subject. The subject will not be excluded from other aspects of the study described in this protocol.

6. Able to understand, read and speak the English language.

Exclusion criteria

1. History of any clinically significant disease or disorder which, in the opinion of the investigator, may either put the potential subject at risk because of participation in the study, or influences the results or the potential subject's ability to participate in the study.

2. History or presence of gastrointestinal, hepatic or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.

3. Any clinically significant illness, medical/surgical procedure, or trauma within 4 weeks of first dosing with investigational medicinal product (IMP).

4. Any clinically significant abnormalities in hematology, clinical chemistry or urinalysis results, as judged by the investigator.

5. Abnormal findings in vital signs, after 10 minutes resting in the supine position, defined as any of the following:

- Systolic blood pressure (SBP) < 90 mmHg or = 140 mmHg

- Diastolic blood pressure (DBP) < 50 mmHg or = 90 mmHg

- Pulse < 45 or > 85 beats per minute (bpm)

6. Any clinically significant abnormalities on the 12-lead electrocardiogram (ECG), as judged by the investigator.

7. Any positive result at screening for serum hepatitis B surface antigen (HBsAg), hepatitis C antibody, and human immunodeficiency virus (HIV) antibodies.

8. Known or suspected history of drug abuse, as judged by the investigator.

9. Has received another new chemical entity (defined as a compound which has not been approved for marketing) within 3 months of first dosing. The period of exclusion begins 3 months after the final dose or one month after the last visit whichever is the longest.

Note: Subjects consented and screened, but not randomized in this study or a previous phase I study, are not excluded.

10. Plasma donation within one month of screening or any blood donation/blood loss > 500 mL during the 3 months prior to screening.

11. History of severe allergy/hypersensitivity or ongoing clinically significant allergy/hypersensitivity, as judged by the investigator or history of hypersensitivity to drugs with a similar chemical structure or class to AZD9977.

12. Current smokers or those who have smoked or used nicotine products within the previous 3 months.

13. Positive screen for drugs of abuse, alcohol or cotinine at screening or for each admission to the study center.

14. Use of drugs with enzyme inducing properties such as St John's Wort within 3 weeks prior to first dosing.

15. Use of any prescribed or non-prescribed medication including antacids, analgesics (other than paracetamol/acetaminophen), herbal remedies, megadose vitamins (intake of 20 to 600 times the recommended daily dose) and minerals during 2 weeks prior to first dosing, or longer if the medication has a long half-life.

16. Known or suspected history of alcohol or drug abuse or excessive intake of alcohol, as judged by the investigator.

17. Involvement of any AstraZeneca or study site employee or their close relatives.

18. Subjects who previously received AZD9977.

19. Judgment by the investigator that the subject should not participate in the study if they have any ongoing or recent (i.e., during the screening period) minor medical complaints that may interfere with the interpretation of study data or are considered unlikely to comply with study procedures, restrictions and requirements.

20. Known allergy to eplerenone or fludrocortisone or any of the constituents (including lactose, which is a constituent of Florinef™).

21. History of galactose intolerance.

22. Any infections or at risk of infection (surgery, trauma, or significant infection) within 90 days of screening, or history of skin abscesses within 90 days of screening.

23. Presence, history or family history of long QT syndrome, hypokalemia, hyperkalemia or Torsades de Pointes.

24. Serum potassium < 3.5 mmol/L or = 5.0 mmol/L at screening or for each admission to the study center.

25. Presence or history of active peptic ulcer.

26. History of any psychiatric disorder (including affective, psychotic, behavioral, irritability, anxiety, sleep disturbances and cognitive disorders) which required specialist psychiatric review.

27. Excessive intake of caffeine containing drinks or food (e.g., coffee, tea and chocolate) as judged by the investigator.

28. Subjects who are vegans or have medical dietary restrictions (vegetarians may be included in the study).

29. Subjects who cannot communicate reliably with the investigator.

30. Vulnerable subjects, e.g., kept in detention, protected adults under guardianship, trusteeship, or committed to an institution by governmental or juridical order.

31. In addition, any of the following is regarded as a criterion for exclusion from the genetic research:

- Previous bone marrow transplant.

- Non-leukocyte depleted whole blood transfusion within 120 days of the date of the genetic sample collection.

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science


Related Conditions & MeSH terms


Intervention

Drug:
AZD9977 oral suspension
AZD9977 oral suspension, single dose
AZD9977 placebo oral suspension
oral suspension, single dose
Fludrocortisone, tablets
Loading dose of 0.5 mg and maintenance doses of 0.1 mg every second hour up to a total dose of 1.0 mg per treatment period (may be modified to up to 1.3 mg based on emerging data)
Eplerenone, tablets
100 mg (2 x 50 mg tablets) single dose, may be modified based on emerging data (will not exceed 500 mg per treatment period)

Locations

Country Name City State
United Kingdom Research Site Harrow

Sponsors (1)

Lead Sponsor Collaborator
AstraZeneca

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Pharmacodynamics of AZD9977 by assessment of sodium/potassium ratio in urine after treatment with eplerenone in comparison with after treatment with a combination of eplerenone and AZD9977 Pharmacodynamics of AZD9977 after single dosing of AZD9977 with fludrocortisone both with and without eplerenone From 2 hours post dose to 6 or 8 hours post dose, depending on the clearance of AZD9977 as determined in a prior study, during each of the 6 treatment periods. Total duration of the study will be up to 10 weeks No
Secondary Pharmacodynamics of AZD9977 by assessment of the sodium/potassium ratio in urine after treatment with AZD9977 placebo in comparison with after treatment with AZD9977 Pharmacodynamics of AZD9977 after single dosing of AZD9977 with fludrocortisone in comparison to AZD9977 placebo From 2 hours post dose to 6 or 8 hours post dose, depending on the clearance of AZD9977 as determined in a prior study, during each of the 6 treatment periods. Total duration of the study will be up to 10 weeks No
Secondary Safety and tolerability of AZD9977 by assessment of the number of adverse events and the number of subjects with adverse events To assess the safety and tolerability of single doses of AZD9977 From screening to post-study visit, up to 10 weeks Yes
Secondary Safety and tolerability of AZD9977 by assessment of blood pressure To assess the safety and tolerability of single doses of AZD9977 From screening to post-study visit, up to 10 weeks Yes
Secondary Safety and tolerability of AZD9977 by assessment of pulse To assess the safety and tolerability of single doses of AZD9977 From screening to post-study visit, up to 10 weeks Yes
Secondary Safety and tolerability of AZD9977 by assessment of electrocardiogram To assess the safety and tolerability of single doses of AZD9977 From screening to post-study visit, up to 10 weeks Yes
Secondary Safety and tolerability of AZD9977 by assessment of physical examination This is a composite of the general appearance, skin, cardiovascular, respiratory, abdomen, head, and neck (including ears, eyes, nose, and throat), lymph nodes, thyroid, musculoskeletal and neurological systems From screening to post-study visit, up to 10 weeks Yes
Secondary Safety and tolerability of AZD9977 by assessment of safety laboratory tests This is a composite of clinical chemistry, hematology and urinalysis From screening to post-study visit, up to 10 weeks Yes
Secondary Pharmacodynamics of AZD9977 by assessment of fractional sodium excretion in urine for each urine collection time interval Pharmacodynamics of AZD9977 after single dosing of AZD9977 with fludrocortisone and/or eplerenone From 8 h before dosing until 24h after dosing No
Secondary Pharmacodynamics of AZD9977 by assessment of total sodium excreted cumulatively and during each of the urine collection intervals Pharmacodynamics of AZD9977 after single dosing of AZD9977 with fludrocortisone and/or eplerenone From 8 h before dosing until 24h after dosing No
Secondary Pharmacodynamics of AZD9977 by assessment of fractional potassium excretion in urine for each urine collection time interval Pharmacodynamics of AZD9977 after single dosing of AZD9977 with fludrocortisone and/or eplerenone From 8 h before dosing until 24h after dosing No
Secondary Pharmacodynamics of AZD9977 by assessment of urine production for each urine collection time interval Pharmacodynamics of AZD9977 after single dosing of AZD9977 with fludrocortisone and/or eplerenone From 8 h before dosing until 24h after dosing No
Secondary Pharmacodynamics of AZD9977 by assessment of total potassium excreted cumulatively and during each of the urine collection intervals Pharmacodynamics of AZD9977 after single dosing of AZD9977 with fludrocortisone and/or eplerenone From 8 h before dosing until 24h after dosing No
Secondary Pharmacodynamics of AZD9977 by assessment of total urine volume excreted cumulatively and during each of the urine collection intervals Pharmacodynamics of AZD9977 after single dosing of AZD9977 with fludrocortisone and/or eplerenone From 8 h before dosing until 24h after dosing No
See also
  Status Clinical Trial Phase
Completed NCT05483998 - A Study to Evaluate Single and Multiple Doses of TLC-2716 in Healthy Participants Phase 1
Recruiting NCT02235012 - Cognitive Biases Under Ketamine N/A
Recruiting NCT02417714 - Prospective Evaluation of Next Generation CT Reconstruction (NextGenIR)
Completed NCT05088343 - Effect of Hetrombopag on the Pharmacokinetics of Rosuvastatin in Healthy Subjects Phase 1
Completed NCT04418973 - Analysis of Breath Volatile Organic Compounds After Dyspnea Induced in the Healthy Subject. N/A
Not yet recruiting NCT06248801 - Vildagliptin and Metformin Tablets 50/1000 mg Relative to GALVUS MET (50mg/1000 mg) Tablets Phase 1
Terminated NCT04068259 - Single Ascending Dose Study of PBI-4547 in Healthy Subjects Phase 1
Completed NCT03279302 - Trial to Evaluate the PK Profile of Glepaglutide (ZP1848) After a Single IV and After Multiple SC Injections in Healthy Subjects Phase 1
Not yet recruiting NCT06233162 - Febuxostat 80 mg Tablets Relative to Feburic® 80 mg Tablets Phase 1
Recruiting NCT04159844 - Evaluation of the Stiffness and Pressure Applied on the Lower Leg by a New Compression Bandage on Healthy Subjects N/A
Completed NCT06137911 - Evaluation of Safety, Tolerability & Pharmacokinetics of JYP0061 in Healthy Adults. Phase 1
Completed NCT04849286 - Measurement of HTL0016878 in Cerebrospinal Fluid Phase 1
Not yet recruiting NCT06233227 - Dutasteride Soft Capsule 0.5 mg Relative to Avodart 0.5 mg Soft Capsule Phase 1
Completed NCT04096157 - A Study to Assess Isavuconazole Following a Single Dose of Isavuconazonium Sulfate Intravenous Solution Via Nasogastric (NG) Tube Compared to a Single Dose of Oral Capsules Under Fasting Conditions in Healthy Participants Phase 1
Completed NCT01200368 - Trial Evaluating a 13-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants Phase 3
Recruiting NCT05805033 - Peri-Implant Soft Tissue Integration in Humans: Influence of Material N/A
Completed NCT04027803 - Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Single Intravenous Doses of BCD-148 and Soliris® Phase 1
Recruiting NCT03467880 - Multicenter Study of Impulse Oscillometry in Chinese N/A
Completed NCT02903095 - Single Ascending Dose Study of TD-1439 in Healthy Subjects Phase 1
Active, not recruiting NCT02341508 - A Phase 1a, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate Lpathomab in Healthy Volunteers Phase 1